Basal expression of interferon regulatory factor 1 drives intrinsic hepatocyte resistance to multiple RNA viruses.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
07 2019
Historique:
received: 15 01 2019
accepted: 06 03 2019
pubmed: 17 4 2019
medline: 14 9 2019
entrez: 17 4 2019
Statut: ppublish

Résumé

Current models of cell-intrinsic immunity to RNA viruses centre on virus-triggered inducible antiviral responses initiated by RIG-I-like receptors or Toll-like receptors that sense pathogen-associated molecular patterns, and signal downstream through interferon regulatory factors (IRFs), transcription factors that induce synthesis of type I and type III interferons

Identifiants

pubmed: 30988429
doi: 10.1038/s41564-019-0425-6
pii: 10.1038/s41564-019-0425-6
pmc: PMC6588457
mid: NIHMS1523237
doi:

Substances chimiques

Interferon Regulatory Factor-1 0
RNA, Small Interfering 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1096-1104

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI103083
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131685
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109965
Pays : United States

Références

Yoneyama, M., Onomoto, K., Jogi, M., Akaboshi, T. & Fujita, T. Viral RNA detection by RIG-I-like receptors. Curr. Opin. Immunol. 32, 48–53 (2015).
doi: 10.1016/j.coi.2014.12.012
Chan, Y. K. & Gack, M. U. Viral evasion of intracellular DNA and RNA sensing. Nat. Rev. Microbiol. 14, 360–373 (2016).
doi: 10.1038/nrmicro.2016.45
Li, K., Chen, Z., Kato, N., Gale, M. Jr. & Lemon, S. M. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-β production in hepatocytes. J. Biol. Chem. 280, 16739–16747 (2005).
doi: 10.1074/jbc.M414139200
Woodson, S. E. & Holbrook, M. R. Infection of hepatocytes with 17-D vaccine-strain yellow fever virus induces a strong pro-inflammatory host response. J. Gen. Virol. 92, 2262–2271 (2011).
doi: 10.1099/vir.0.031617-0
Feng, H. et al. NLRX1 promotes immediate IRF1-directed antiviral responses by limiting dsRNA-activated translational inhibition mediated by PKR. Nat. Immunol. 18, 1299–1309 (2017).
doi: 10.1038/ni.3853
Lemon, S. M., Ott, J. J., Van Damme, P. & Shouval, D. Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J. Hepatol. 68, 167–184 (2018).
doi: 10.1016/j.jhep.2017.08.034
Hirai-Yuki, A. et al. MAVS-dependent host species range and pathogenicity of human hepatitis A virus. Science 353, 1541–1545 (2016).
doi: 10.1126/science.aaf8325
Taki, S. et al. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6, 673–679 (1997).
doi: 10.1016/S1074-7613(00)80443-4
White, L. C. et al. Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8
doi: 10.1016/S1074-7613(00)80262-9
Fujita, T., Kimura, Y., Miyamoto, M., Barsoumian, E. L. & Taniguchi, T. Induction of endogenous IFN-α and IFN-β genes by a regulatory transcription factor, IRF-1. Nature 337, 270–272 (1989).
doi: 10.1038/337270a0
Odendall, C. et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat. Immunol. 15, 717–726 (2014).
doi: 10.1038/ni.2915
Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481–485 (2011).
doi: 10.1038/nature09907
Dixit, E. et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141, 668–681 (2010).
doi: 10.1016/j.cell.2010.04.018
Sumpter, R.Jr et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79, 2689–2699 (2005).
doi: 10.1128/JVI.79.5.2689-2699.2005
Leblanc, J. F., Cohen, L., Rodrigues, M. & Hiscott, J. Synergism between distinct enhanson domains in viral induction of the human beta interferon gene. Mol. Cell. Biol. 10, 3987–3993 (1990).
doi: 10.1128/MCB.10.8.3987
Miyamoto, M. et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell 54, 903–913 (1988).
doi: 10.1016/S0092-8674(88)91307-4
Tanaka, N., Kawakami, T. & Taniguchi, T. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. Mol. Cell. Biol. 13, 4531–4538 (1993).
doi: 10.1128/MCB.13.8.4531
Oikawa, T. et al. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nat. Commun. 6, 8070 (2015).
doi: 10.1038/ncomms9070
Uyama, T., Jin, X. H., Tsuboi, K., Tonai, T. & Ueda, N. Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes. Biochim. Biophys. Acta 1791, 1114–1124 (2009).
doi: 10.1016/j.bbalip.2009.07.001
Staring, J. et al. PLA2G16 represents a switch between entry and clearance of Picornaviridae. Nature 541, 412–416 (2017).
doi: 10.1038/nature21032
Hsu, T. H. et al. Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells. Cell Death Differ. 22, 801–814 (2015).
doi: 10.1038/cdd.2014.175
Ou, C. C. et al. Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis 29, 299–306 (2008).
doi: 10.1093/carcin/bgm263
Chiang, G. G. & Abraham, R. T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280, 25485–25490 (2005).
doi: 10.1074/jbc.M501707200
Figueiredo, V. C., Markworth, J. F. & Cameron-Smith, D. Considerations on mTOR regulation at serine 2448: implications for muscle metabolism studies. Cell. Mol. Life Sci. 74, 2537–2545 (2017).
doi: 10.1007/s00018-017-2481-5
Wang, J. et al. Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7. J. Immunol. 191, 3393–3399 (2013).
doi: 10.4049/jimmunol.1300740
McCarthy, M. K. & Weinberg, J. B. The immunoproteasome and viral infection: a complex regulator of inflammation. Front. Microbiol. 6, 21 (2015).
doi: 10.3389/fmicb.2015.00021
Verweij, M. C. et al. Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution. PLoS Pathog. 11, e1004743 (2015).
doi: 10.1371/journal.ppat.1004743
Schoggins, J. W. et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505, 691–695 (2014).
doi: 10.1038/nature12862
Langlais, D., Barreiro, L. B. & Gros, P. The macrophage IRF8/IRF1 regulome is required for protection against infections and is associated with chronic inflammation. J. Exp. Med. 213, 585–603 (2016).
doi: 10.1084/jem.20151764
Nair, S., Poddar, S., Shimak, R. M. & Diamond, M. S. Interferon regulatory factor-1 (IRF-1) protects against chikungunya virus induced immunopathology by restricting infection in muscle cells. J. Virol. 91, e01419-17 (2017).
doi: 10.1128/JVI.01419-17
Dansako, H. et al. Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. PLoS Pathog. 9, e1003345 (2013).
doi: 10.1371/journal.ppat.1003345
Yamane, D. et al. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat. Med. 20, 927–935 (2014).
doi: 10.1038/nm.3610
Yamane, D. et al. Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3′ variants. Nucleic Acids Res. 45, 4743–4755 (2017).
pubmed: 28082397 pmcid: 5416874
Feng, Z. et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 496, 367–371 (2013).
doi: 10.1038/nature12029
Hishiki, T. et al. Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication. Biochem. Bioph. Res. Co. 448, 95–100 (2014).
doi: 10.1016/j.bbrc.2014.04.081
Beard, M. R., Cohen, L., Lemon, S. M. & Martin, A. Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction. J. Virol. 75, 1414–1426 (2001).
doi: 10.1128/JVI.75.3.1414-1426.2001
Binn, L. N. et al. Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J. Clin. Microbiol. 20, 28–33 (1984).
pubmed: 6086708 pmcid: 271239
Matsuda, M. et al. High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon. Sci. Rep. 8, 16624 (2018).
doi: 10.1038/s41598-018-34865-y
Yi, M. & Lemon, S. M. Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells. J. Virol. 76, 1171–1180 (2002).
doi: 10.1128/JVI.76.3.1171-1180.2002
Baba, T. et al. Phosphatidic acid (PA)-preferring phospholipase A1 regulates mitochondrial dynamics. J. Biol. Chem. 289, 11497–11511 (2014).
doi: 10.1074/jbc.M113.531921
Imae, R. et al. LYCAT, a homologue of C. elegans acl-8, acl-9, and acl-10, determines the fatty acid composition of phosphatidylinositol in mice. J. Lipid Res. 53, 335–347 (2012).
doi: 10.1194/jlr.M018655
Kielkowska, A. et al. A new approach to measuring phosphoinositides in cells by mass spectrometry. Adv. Biol. Regul. 54, 131–141 (2014).
doi: 10.1016/j.jbior.2013.09.001
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
doi: 10.1093/bioinformatics/bts635
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).
doi: 10.1038/nmeth.4197
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
doi: 10.1186/s13059-014-0550-8

Auteurs

Daisuke Yamane (D)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. yamane-ds@igakuken.or.jp.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. yamane-ds@igakuken.or.jp.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. yamane-ds@igakuken.or.jp.
Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan. yamane-ds@igakuken.or.jp.

Hui Feng (H)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Efraín E Rivera-Serrano (EE)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Sara R Selitsky (SR)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.

Asuka Hirai-Yuki (A)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Experimental Animal Research, National Institute of Infectious Diseases, Tokyo, Japan.

Anshuman Das (A)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Kevin L McKnight (KL)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Ichiro Misumi (I)

Department of Microbiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Immunology and Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Lucinda Hensley (L)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

William Lovell (W)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Olga González-López (O)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Ryosuke Suzuki (R)

Department of Virology II, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.

Mami Matsuda (M)

Department of Virology II, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.

Hiroki Nakanishi (H)

Research Center for Biosignaling, Akita University,, Akita, Japan.

Takayo Ohto-Nakanishi (T)

Lipidome Lab Co., Ltd,, Akita, Japan.

Takayuki Hishiki (T)

Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.

Eliane Wauthier (E)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Cell Biology and Physiology Program in Molecular Biology and Biotechnology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Tsunekazu Oikawa (T)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Cell Biology and Physiology Program in Molecular Biology and Biotechnology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Division of Gastroenterology and Hepatology, Depertment of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Kouichi Morita (K)

Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.

Lola M Reid (LM)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Cell Biology and Physiology Program in Molecular Biology and Biotechnology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Praveen Sethupathy (P)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.

Michinori Kohara (M)

Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.

Jason K Whitmire (JK)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Microbiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Immunology and Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Stanley M Lemon (SM)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. smlemon@med.unc.edu.
Department of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. smlemon@med.unc.edu.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. smlemon@med.unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH